Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer
Kohsuke Isomoto(Kindai University Hospital), Kazuhiko Nakagawa(Dana-Farber Cancer Institute), Yasutaka Chiba(Kindai University Hospital), Toshihide Yokoyama(Kurashiki Central Hospital), Hidetoshi Hayashi(Kindai University Sakai Hospital), Shuta Tomida(Okayama University), Koji Haratani, Junko Tanizaki(Kindai University), Akihiko Ito(Kindai University), Masayuki Takeda(Kindai University), Takashi Ogura(Kanagawa Cardiovascular and Respiratory Center), Tadashi Ishida(Kurashiki Central Hospital), Ryoji Kato(Kindai University), Kaoru Tanaka(Kindai University), Takashi Niwa(Kurashiki Central Hospital), Yasushi Fukuda(Kurashiki Central Hospital), Shigeki Shimizu(Kindai University)
Cited by 244
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k